Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

Robert L. Findling1 · Shawn A. Candler2 · Azmi F. Nasser2 · Stefan Schwabe2 · Chungping Yu2 · Jennie Garcia-Olivares2 · Welton O’Neal2 · Jeffrey H. Newcorn3

Accepted: 3 May 2021 / Published online: 18 May 2021 © The Author(s) 2021

Abstract
Viloxazine has a long history of clinical use in Europe as an antidepressant, and has recently been repurposed into an extended-release form for the treatment of attention-deficit/hyperactivity disorder in the USA. An immediate-release formulation was approved for the treatment of depression in the UK in 1974, and was subsequently marketed there and in several European countries for 30 years with no major safety concerns. In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was associated with a relatively low risk for cardiotoxicity. Gastrointestinal symptoms were the most commonly reported side effects. The therapeutic effects of viloxazine are thought to be primarily the result of its action as a norepinephrine reuptake inhibitor, although in vitro and preclinical in vivo animal data suggest that viloxazine may also impact the serotonergic system. This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investigations, and acquired unpublished historical study reports from both open-label and blinded controlled clinical trials. We review the chemical properties, mechanism of action, safety, and tolerability across these studies, and discuss the contemporary rationale for the development of this agent as an extended-release oral formulation for the treatment of attention-deficit/hyperactivity disorder.

1 Introduction
Viloxazine extended-release (ER) is a novel nonstimulant that was approved in April 2021 by the US Food and Drug Administration under the trade name Qelbree™ for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. The original immediate-release (IR) viloxazine formulation was discovered incidentally during an attempt to synthesize molecules chemically related to propranolol with central nervous system (CNS)-modulating properties [1] (see Fig. 1 for the chemical structure). Subsequently, an IR formulation was developed and approved for the treatment of adults with depression in the UK in 1974, and marketed there and in several European countries for over 30 years. While commercially available, viloxazine was used in both adult and elderly patients as a two-times or three-times daily treatment [2], and was distributed under the trade names Viloxazin [3], Emovit [4], Viloxazina [5], Viloxazinum [5], Vivarint [6], Vicilan [2], and Vivalan [7].

In 1984, viloxazine was assigned an orphan drug designation in the USA under the brand name Catatrol for the treatment of cataplexy and narcolepsy, but, for unknown reasons, was never approved for either indication [8]. The IR formulation of viloxazine was discontinued in the early 2000s for business reasons unrelated to safety and efficacy [5, 9], and at the time of this publication has not been previously approved and marketed in the USA for any indication. Here, we review what is known about the chemical properties and clinical activity of viloxazine from its previous use in adult patients with depression, including individuals with comorbid conditions such as anxiety, alcoholism, and epilepsy, as well as recent clinical trials of the new ER formulation, viloxazine ER.
To review the basic and clinical science of viloxazine, preclinical and clinical studies and reviews were searched on PubMed (search terms: “Viloxazine,” “Viloxazin,” “Emovit,” “Viloxazina,” “Viloxazinum,” and “Vivalan”). In addition, meeting proceedings from the International Vivalan [Viloxazine] Symposium in England in 1975 [10], and study reports from 1973 to 1976 were obtained as part of the acquisition of viloxazine by Supernus Pharmaceuticals, Inc. From these study reports, we identified 23 open-label trials (total, \(N = 605\)) and 14 single-blind or double-blind (total, \(N = 821\); viloxazine, \(n = 447\)) controlled trials investigating the utility and safety of viloxazine for depression and/or anxiety, all of which were conducted prior to 1976. Safety and tolerability data from the unpublished trials described in these study reports may be informative to the application of viloxazine ER in the treatment of ADHD, and are summarized in Tables 1 and 2, respectively.

### 2 Pharmacology and Mechanism of Action

The primary CNS targets of viloxazine appear to be in the monoaminergic systems, although viloxazine differs from many other known antidepressants in that its mechanism of action is not linked to inhibition of serotonin or dopamine reuptake [11, 12]. Viloxazine has been shown to increase brain norepinephrine concentrations [13] via norepinephrine reuptake blockade [11, 14], with no direct effect on in vitro norepinephrine release [14]. A contemporary study confirmed that viloxazine demonstrates moderate inhibitory activity at the norepinephrine transporter (half-maximal inhibitory concentration in the 0.3-\(\mu\)M range), significantly increases extracellular norepinephrine levels across several brain regions (assessed in the prefrontal cortex, nucleus accumbens, and amygdala), and possesses weak antagonistic effects at the adrenergic \(\beta_2\) and adrenergic \(\alpha_{1B}\) norepinephrine receptors [15].

Data from the 1970s showed that viloxazine does not significantly inhibit the uptake of serotonin into human blood platelets [1] or CNS tissue [11, 12]. Viloxazine increased neuronal sensitivity to serotonin [16, 17], and potentiated both the 5-hydroxytryptophan (precursor to serotonin)-induced behavioral syndrome in mice and the 5-hydroxytryptophan-induced hind-limb extensor reflex in rats, thought to reflect increased activation of serotonin receptors [12]. Notably, viloxazine has been shown to facilitate basal serotonin release from rat striatal brain slices [14]. A recent preclinical study showed that viloxazine increases serotonin levels in the prefrontal cortex, nucleus accumbens, and amygdala in vivo [15], and is an agonist at serotoninergic 5-HT\(_{2C}\) receptors, an antagonist at 5-HT\(_{2B}\) receptors, and a weak antagonist at 5-HT\(_{7}\) receptors [15]. Importantly, this action on serotonin receptors may play a role in serotonin release: antagonism of 5-HT\(_{2B}\) receptors located on GABAergic interneurons has been shown to disinhibit tonic inhibitory control of serotonin neurons innervating the medial prefrontal cortex, indirectly stimulating serotonin release in this region [18].

Initial reports suggested that viloxazine could produce modest and transient dopamine increases in the CNS, though to a lesser degree than norepinephrine or serotonin.
Table 1: Overview of dosing and tolerability across unpublished open-label trials from 1973 to 1976 investigating viloxazine immediate-release (original formulation) in adults with depression

| Principal investigator, study site, year | Study title | Number of patients [treatment duration] | Patient type(s)/disorder(s) [trial setting] | Viloxazine dose, mg/day [regimen] | Available tolerability commentary |
|------------------------------------------|-------------|-----------------------------------------|---------------------------------------------|----------------------------------|----------------------------------|
| Browne, UK, 1973                         | Open study of viloxazine in depression | 20 [≤ 42 days, mean 20 days] | Depressive disorders (psychiatric comorbidities allowed) [inpatients] | 100–400 mg [100 mg qd/bid/tid/qid] | Most common AE: nausea |
| Edwards, UK, 1973                        | Open pilot study of viloxazine in depression | 12 [≤ 52 days, mean 21 days] | Depressive disorders [inpatients] | 240–420 mg [80, 100, 120, 140 mg tid] | 8/12 reported AEs. Most common AE: upper gastrointestinal effects, nausea |
| Engersdorf, Austria, 1973                | Open study of viloxazine in depressive illness | 19 [14 days, mean 11 days] | Sustained depressive disorder [outpatients] | 200 mg or 300 mg [100 mg bid/tid] | 8/19 reported AEs, generally mild and transient |
| Le Poidevin, UK, 1973                    | Open study of viloxazine in depression | 11 [≤ 56 days, mean 35 days] | Severe depression (psychiatric comorbidities allowed) [inpatients] | 120–300 mg [40 mg, 80 mg, 100 mg tid] | 3/11 reported AEs |
| Millar, UK, 1973                         | Open study of viloxazine in depression | 20 [≤ 120 days, mean 38 days] | Depressive disorders [inpatients] | 150–300 mg [50 mg tid; 100 mg bid/tid] | Most common AE: upper gastrointestinal effects |
| Wheatley, UK, 1973                       | General Practice Research Group assessment of antidepressant activity of viloxazine | 77 (dose-ranging) [28 days] | Depressive disorder [outpatients] | 120–300 mg [40 mg tid; 100 mg bid/tid] | Most common AE: nausea (generally transient) |
| Wilkinson, UK, 1973                      | Open study of viloxazine in anxiety and depression | 12 [≤ 392 days, mean 111 days] | Depression, depression and anxiety, anxiety [outpatients] | 60–300 mg [20 mg tid; 100 mg bid/tid] | 6/12 reported AEs. Most common AE: nausea (n = 4) |
| Brion, France, 1974                      | Open study of viloxazine in depression | 90 [≤ 240 days, mean 61 days] | Depressive disorders (psychiatric comorbidities allowed) [outpatients] | 200–300 mg [100 mg bid/tid] | 31/90 reported AEs, 7 leading to withdrawal. Most common AE: Gastrointestinal effects (transient) |
| Merskey, UK, 1974                        | Open study of viloxazine in drug-resistant depression | 20 [≤ 168 days, mean 39 days] | Treatment-resistant depression [inpatients] | 150–300 mg [50 mg tid; 100 mg bid/tid] | 8/20 reported AEs |
| Milovanovic, Yugoslavia, 1974            | Open trial of viloxazine in chronic endogenous depression | 22 [≤ 60 days, mean 47 days] | Chronic depression [inpatients] | 150–300 mg [50 mg tid; 100 mg bid/tid] | Most common AE: nausea and vomiting (n = 1, resolved with medication) |
| Roelandts, Belgium, 1974                 | Open study of viloxazine in depressed outpatients | 28 [≤ 63 days, mean 29 days] | Sustained affective disorder [outpatients] | 200 mg or 300 mg [100 mg bid/tid] | 8 withdrawals because of AEs, nausea (n = 5), worsening anxiety (n = 3) |
| Delteil, France, 1975                    | Open clinical trial of viloxazine hydrochloride in depression | 42 [≤ 13 months] | Depressive disorders (psychiatric comorbidities allowed) [inpatients] | 150–600 mg [50 or 200 mg tid] | Well tolerated |
| De Francisco and Castilla, Mexico, 1975   | Viloxazine: a bicyclic anti-depressive | 16 [≤ 8 weeks] | Depression [outpatients] | 100–400 mg | 1/16 withdrew because of AEs (nausea, vomiting). Most common AEs: nausea, vomiting, reduced appetite/weight loss |

*AE: Adverse event.*
Other in vitro studies found no effect on dopamine release in striatal tissue [14], and little affinity for, or potency at, either dopamine receptors or the transporter [11, 14, 15, 19]. Recently, viloxazine was shown in a preclinical rodent model to increase dopamine levels in vivo appreciably in the prefrontal cortex, moderately in the amygdala, and minimally in the nucleus accumbens [15], which likely reflects a combination of direct (via the noradrenaline transporter, which also manages reuptake of dopamine in the prefrontal cortex) and indirect effects. The minimal impact of viloxazine on dopamine in the nucleus accumbens, a region known for its key role in substance use disorders [20, 21], may be associated with a low abuse liability [22]. Notably, dysregulated dopamine signaling in the prefrontal cortex and amygdala has been implicated in the pathophysiology of ADHD [23–28], and is a primary target of many effective ADHD medications [27, 29, 30].

In contrast to many first-generation antidepressants (i.e., tricyclic antidepressants [TCAs] and monoamine oxidase inhibitors), viloxazine demonstrates negligible activity in the cholinergic system [12, 13], and lacks any appreciable activity towards histamine [13, 31]. It reduces the responsiveness of rat cortical neurons to acetylcholine [32, 33], shows negligible binding to the choline transporter, and essentially no impact on acetylcholine levels in the prefrontal cortex, nucleus accumbens, or amygdala [15, 34]. Early in vitro studies suggested viloxazine was not a significant inhibitor of monoamine oxidase [1, 12], but it was later characterized as a very weak, competitive, and reversible inhibitor of monoamine oxidase A and B [35]. A recent study found viloxazine to demonstrate weak competitive inhibition (<25%) at histamine receptors H1 and H2 and muscarinic receptors M1–4, and notably low affinity towards monoamine oxidase A [15].

### Table 1 (continued)

| Principal investigator, study site, year | Study title | Number of patients [treatment duration] | Patient type(s)/disorder(s) [trial setting] | Viloxazine dose, mg/day [regimen] | Available tolerability commentary | AEs | Acute withdrawal 
|---|---|---|---|---|---|---|---
| Gorceix, France, 1975 | Open study of viloxazine in depression | 20 [1–6 months, mean 67 days] | Depressive disorders (psychiatric comorbidities allowed) [inpatients] | 200–400 mg [100 bid/tid/qid] | No withdrawals because of AEs | | 
| Coppen, UK, date unknownb | Familiarization study of viloxazine in depression | 5 [3 weeks, mean 19 days] | Endogenous depression [inpatients] | 120–400 mg [40, 80 tid, 100 mg qid] | Most common AE: nausea (r = 1; resolved with medication) | Most common AE: insomnia (mild, transient) | 
| Welner, Denmark, date unknownb | Open study of viloxazine in depression | 21 [≤ 41 days, mean 16 days] | Moderate-severe depressive disorder [inpatients] | 200–400 mg [100 mg bid/tid/qid] | | | 
| | | | | | | | 

AEs, adverse events; bid, twice a day; qd, once a day; tid, three times a day

The tolerability commentary was compiled per available safety statements in acquired study reports.

A tolerability commentary compiled for all available safety statements of trials conducted prior to 1976.

Table 1. Viloxazone in adult patients with depressive disorders.

We were able to identify 37 clinical investigations assessing viloxazine dosing in adult patients with depressive disorders (including studies in subjects with comorbid anxiety disorders as well as epilepsy) [4] for those that remain unpublished. Across these trials, viloxazine was investigated at a dose range of 50–600 mg/day, administered two to four times daily. The typical target dose for depression was 300–400 mg/day in adults or 100–200 mg/day in elderly patients, generally administered twice or three times daily [4]. Contemporary studies in the treatment of ADHD have administered viloxazine ER at daily doses of 100–400 mg in children (aged 6–11 years), and 200–600 mg in adolescents (aged 12–17 years) and 200–600 mg in adults (aged 18–65 years) [36–40].
Table 2  Overview of dosing and tolerability across unpublished double-blind and single-blind clinical trials from 1974 to 1976 investigating viloxazine immediate-release (original formulation) in adults with depression

| Principal investigator, study site, year | Study title | Number of patients [treatment duration] | Patient type(s)/disorder(s) | Viloxazine dose, mg/day [regimen] | Available tolerability commentary

| Ekdawi, UK, 1974 | Double-blind controlled comparison of imipramine and viloxazine in depression | 59 (29 viloxazine) [6 weeks, compared to imipramine] | Depression [inpatients] | 300 mg [100 mg tid] | 50% treated patients had no AEs after 2 weeks

| Hamilton, UK, 1974 | Double-blind between-patient study of viloxazine vs. placebo in depression | 36 (21 viloxazine) [1 week] | Depression [inpatients] | 400 mg [100 mg qid] | 20/21 treated, 12/15 placebo reported side effects

| Magnus, UK, 1974 | Double-blind four-way crossover study of viloxazine, perphenazine, the combination, and placebo in depression | 24 [2 weeks per drug, crossover design compared to perphenazine] | Depression and anxiety [inpatients] | 150 mg [50 mg tid] | Most common AE: mild nausea

| Magnus, UK, 1974 | Double-blind four-way crossover study of viloxazine, diazepam, the combination, and placebo in depression | 27 [2 weeks per drug, crossover design compared to diazepam] | Depression and anxiety [outpatient] | 150 mg [50 mg tid] | AEs were not significantly greater than placebo

| Floru and Czarny, Germany, 1976 | Double-blind study with the new antidepressant viloxazine compared to imipramine in 50 inpatients [translated] | 50 (25 viloxazine) [4 weeks, compared to imipramine] | Depression [inpatient] | 150–300 mg | Lower withdrawal rate (n = 2) compared to imipramine (n = 7)

| Frank, UK, date unknownb | Double-blind study of low doses of viloxazine vs. placebo in mild depression in general practice | 63 (30 viloxazine) [2 weeks] | Mild depression [outpatient] | 100 mg [50 mg bid] | Significantly higher withdrawal rate because of AEs than placebo, lower AEs than placebo in completers

AEs adverse events, bid twice a day, qid four times a day, tid three times a day

*T tolerability commentary compiled per available safety statements in acquired study reports

*b Data are from acquired unpublished study reports of trials conducted prior to 1976
4 Pharmacokinetics

The pharmacokinetic profile of IR viloxazine has been well characterized in adult patients with depression. Orally administered viloxazine exhibited a short plasma half-life of 2.5 hours after being well absorbed through the small intestine [41]. Maximum blood concentrations were proportional to the oral dosage, achieved 1–4 h after a single dose [41, 42], with an average oral bioavailability of 85% [42]. The clearance rate after intravenous dosing was found to be 124 ± 11 mL/hour/kg, and the volume of distribution was 0.73 ± 0.28 L/kg [42]. Viloxazine is extensively metabolized, with only 12–15% of the drug being excreted unchanged, and, along with its metabolites, is rapidly eliminated via the kidneys [43, 44]. In both animal and human studies, viloxazine is thought to be responsible for all observed effects, as its metabolites are thought to be essentially inactive [43, 44]. Across species (including rodents, rabbits, canines, and primates) and in humans, viloxazine has a rapid clearance rate, with the majority (90%) of orally administered drug excreted through the urine within 24 hours, and only 2% excreted through fecal matter [43]. A clinical study of two healthy male volunteers given 40 or 100 mg of 14C-viloxazine indicated that the half-life for excretion in the urine was approximately 4–5 hours [43].

5 Efficacy and Safety of Viloxazine in CNS Conditions: Depression, Anxiety, Alcoholism, and Epilepsy

5.1 Clinical Efficacy

In numerous double-blind and open-label studies, viloxazine was effective in treating various types of depressive disorders (some of which are not included in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [45]), including endogenous, neurotic, psychotic, and reactive depression, chronic and severe depression, and depression with comorbid conditions (reviewed in [2] and [46]). Across several studies in cohorts with depression, viloxazine reduced not only depressive symptoms but concomitant symptoms of anxiety ([7, 47, 48], also reviewed in [2]) and alcohol abuse in patients with comorbid alcohol dependence [49]. In a multicenter trial of 115 patients with moderate-to-severe depression, viloxazine was also effective in patients whose depression had not responded to prior antidepressant treatment [7]. Compared with other available antidepressants at the time (e.g., imipramine, amitriptyline), viloxazine was considered to be as effective in reducing symptoms of depression, but with better tolerability [2, 46, 47].

Viloxazine has only twice been directly compared with later antidepressants (and to our knowledge, never with contemporary antidepressants). A double-blind study comparing citalopram and viloxazine in severely depressed patients administered each drug via a slow-drop infusion for 2 weeks followed by oral administration for the following 4 weeks [50]. Both drugs improved scores on depression assessments (e.g., Montgomery–Åsberg Depression Rating Scale) and the Clinical Global Impressions–Improvement scale at both time points (i.e., 14 and 42 days), although this improvement was significantly greater for citalopram [50]. A single-blind trial comparing 4 weeks of nomifensin vs viloxazine (150 mg/day) administration in elderly depressed patients again showed significant improvements on the Hamilton Rating Scale for depression with both treatments [51].

5.2 Safety Profile

Because viloxazine was first developed in the 1970s and has been off the market since the 2000s (depending on the country), available toxicity data were obtained using the methodological standards and comparator treatments available at the time (i.e., TCAs). Viloxazine was generally considered to have a comparatively lower cardiovascular risk than the TCAs and was associated with normal electrocardiogram recordings (e.g., intra-cardiac conduction), even in cases of overdose [52, 53]. In historic studies, viloxazine also did not increase the risk of adrenaline-induced cardiac arrhythmias [2, 52]. In a contemporary study using supratherapeutic doses of viloxazine ER (1800 mg) in healthy adults, there was no effect on cardiac repolarization or other electrocardiogram parameters [54]. Minimal anticholinergic effects were found in human double-blind randomized studies of viloxazine 100 mg vs imipramine 50 mg [55, 56], though both drugs induced transient tachycardia 4 h post-dose [55].

Viloxazine was shown to have a relatively high median lethal dose (LD50) in animal studies, specifically, 500–1000 mg/kg in the mouse and 2000 mg/kg in the rat when administered orally, and 60 mg/kg in mice and 60–77 mg/kg in rats when administered intravenously [1, 5, 52]. There are relatively few documented suicide attempts by humans taking viloxazine [2, 52]. In a 1976 report of 12 cases of drug overdose, doses ranged from 1 to 6.5 g [52]. Gastric lavage and/or forced diuresis was performed and all 12 patients fully recovered [52]. However, a separate account reported one overdose death following ingestion of an unknown amount of medication where the patient received no medical treatment [2]. Given these data in the context of the long history of viloxazine of safe use as an antidepressant, additional studies to identify populations that may be particularly...
vulnerable to viloxazine toxicity may be informative in the future.

In preclinical rodent and nonhuman primate models, viloxazine administered at normal therapeutic concentrations was associated with anticonvulsant activity [1, 13, 57]. Clinical studies using viloxazine IR with or without concomitant anticonvulsant therapy described the drug to be non-epileptogenic or, at least, less epileptogenic than contemporaneous antidepressants; as a result, it was also studied as a possible treatment for depressed patients with epilepsy [42, 58, 59]. Importantly, viloxazine was found to induce elevations of plasma carbamazepine and carbamazepine-10,11-epoxide concentrations [59], while a later study showed that several epileptic drugs (administered in patients with epilepsy) did not alter the pharmacokinetics of viloxazine relative to controls [42]. Viloxazine was ultimately not contraindicated for depressed patients with epilepsy [46, 58].

In the aforementioned trial comparing nomifensin vs viloxazine in elderly patients, sinus tachycardia was reported in two patients (one in each group) [51]. Similarly, there were no major differences in safety outcomes when compared with citalopram [50]. Throughout the literature, there has been no mention of dose tapering, nor has it been evaluated in contemporary studies.

### 5.3 Tolerability

Viloxazine IR was generally well tolerated in clinical studies, with the most frequent side effects including gastrointestinal disturbances such as nausea and vomiting, as well as headache, dry mouth, and fatigue [2, 46–48, 50]. In a multicenter study of 115 adults with moderate-to-severe depression administered 150–300 mg of viloxazine, nausea and fatigue occurred in 13.2% and 9.4% of patients, respectively, with a relatively low incidence of headache (4.7%), vomiting (3.8%), and dry mouth (1.9%) [7]. In two separate studies of patients with mild-to-moderate depression, 150–200 mg/day of viloxazine was found to be efficacious in reducing symptoms of depression and anxiety, with mild side effects that were primarily gastrointestinal in nature [47, 48]. In an analysis of 771 patients across 29 studies, the dropout rate from gastrointestinal symptoms such as nausea and vomiting was 6.9% [60]. In some cases, viloxazine at twice-daily 100-mg doses disrupted sleep patterns (i.e., broken and reduced sleep, decreased rapid eye movement sleep) [61] and at 100 mg/day depressed the critical flicker frequency (a test of general CNS stimulation or depression), though this effect was not seen at lower doses [56]. Double-blind, placebo-controlled crossover studies of low doses (20–80 mg) in healthy volunteers indicated no significant differences between viloxazine and placebo on assessments of reaction time, coordination, or cognitive task performance [47, 62]. Of note, 150–300 mg viloxazine was found to have fewer anticholinergic effects and sedation compared with the TCAs, but nausea and vomiting were common complaints and thought to be dose related [2].

Although the mechanism of action responsible for the reported gastrointestinal side effects (e.g., nausea, vomiting) is unknown, these adverse events have been most pronounced at the onset of treatment and are generally transient in nature, frequently resolving as treatment continues [60], and have been shown to be minimized by gradual introduction of the drug [2]. Ongoing research has considered whether an ER formulation of viloxazine may help mitigate some of the aforementioned gastrointestinal side effects. Recent phase III [36–39] studies investigating the ER formulation at 100–600 mg/day in pediatric patients (i.e., children and adolescents, aged 6–17 years) diagnosed with ADHD found the incidence of nausea and vomiting for viloxazine to be 9.8%, vs 4.1% for placebo.

### 6 Future of Viloxazine: A Potential New Application in ADHD

The therapeutic effects of viloxazine for ADHD are thought to be the result of its action as a norepinephrine reuptake inhibitor. However, demonstrated in vitro and preclinical in vivo activity on norepinephrine and serotonin, as well as direct and downfield indirect effects on dopamine, may be relevant to current applications in ADHD, given the role these neurotransmitters have in regulating attentional and behavioral control [25, 63–67]. Norepinephrine has long been implicated in ADHD pathophysiology [25, 63, 66], and serotonin has also been suggested to play a role in the hyperactivity/impulsivity deficits associated with ADHD [64, 65]. In addition, the effects of viloxazine on dopamine, particularly in the prefrontal cortex, could also contribute to its therapeutic effects [23–26, 28]. Further research is required to address these questions.

Viloxazine was found to be effective for ADHD symptoms and generally well tolerated, as demonstrated in several recent randomized, double-blind, placebo-controlled, phase II and III clinical trials [36–39, 68]. In a recent phase II trial in children aged 6–12 years with ADHD (n = 222), treatment-emergent AEs (TEAEs) were generally mild or moderate, with only three severe TEAEs reported (tearfulness, irritability, and decreased appetite) [68]. In four subsequent phase III trials in children aged 6–11 years [36, 37] and adolescents aged 12–17 years [38, 39], viloxazine ER was well-tolerated over 6–8 weeks of treatment (pooled N = 1117). The most frequently reported AEs were somnolence (14.5%), headache (10.8%), and

△ Adis
decreased appetite (8.1%), with low discontinuation rates because of TEAEs (4% averaged across all trials), less than 1% of subjects reporting a serious TEAE, and no deaths [36–39].

In three of these four phase III trials, statistically significant improvements in ADHD-Rating Scale, Fifth Edition total scores (the primary endpoint) were reported as soon as 1 week following the onset of once-daily treatment with viloxazine ER 100 mg, 200 mg, and 400 mg, relative to placebo [36–38]. In the fourth phase III trial (adolescents, N = 292), the primary efficacy endpoint (improvement on ADHD-Rating Scale, Fifth Edition total scores) did not reach statistical significance for once-daily viloxazine ER 600 mg, despite being statistically significant for patients treated with the 400-mg dose [39]. Why the 400-mg dose was more effective than the higher 600-mg dose relative to placebo in reducing ADHD symptoms is unclear.

The introduction of another nonstimulant option has potential utility in augmenting the therapeutic armamentarium. First-line treatment for ADHD usually includes stimulant pharmacotherapy, as stimulants are associated with near-immediate onset of effect and greater efficacy in improving ADHD outcomes than current nonstimulants [69–71]. However, there are also relative or labeled contraindications to stimulant use in the presence of several comorbid conditions (e.g., insomnia, anorexia), as stimulants are thought to possibly exacerbate these conditions, at least in some individuals [72–76]. Further, most stimulant formulations have a relatively short (e.g., 3–12 h) duration of action [76] (although new formulations such as Mydayis® and Adhansia XR® have labeled efficacy up to 16 h [77, 78]), thus consistent treatment throughout the day can be difficult to achieve. In certain situations, stimulants can fail to provide satisfactory symptom control [79], and have a known potential for abuse [22]. Several Food and Drug Administration-approved nonstimulant ADHD treatment options are currently available, including atomoxetine, guanfacine ER, and clonidine ER, and may be prescribed either alone or in combination with stimulant therapy [80–83]. However, nonstimulants, which are generally less effective and have a slower onset of effect than stimulants [84], are also not without limitations. For example, they have been associated with minor changes in blood pressure or cardiovascular risk [85–87], precipitation of secondary mania [88, 89], and suicidal ideation [90], although these events are rare and generally restricted to vulnerable populations with pre-existing conditions.

Viloxazine ER could help address these limitations and also provide an alternative non-stimulant option. To date, there have been no direct efficacy comparisons between viloxazine ER and other ADHD treatments (e.g., atomoxetine, stimulants), nor has their efficacy in combination been tested. Other studies of the efficacy and safety of viloxazine ER in adults are ongoing, as are long-term efficacy and safety studies in both pediatric and adult populations.

7 Conclusions, Future Perspectives, and Implications for Daily Practice

The pharmacokinetic, pharmacodynamic, and safety profiles of viloxazine have been investigated in numerous studies over several decades, predominantly in adults with depression, alone, or in the presence of comorbid conditions (e.g., anxiety disorders, alcoholism, epilepsy). During its period of commercial use in Europe beginning in the 1970s, the safety profile of viloxazine was well established [2, 46]. Although it has demonstrated in vitro and in vivo preclinical activity on both norepinephrine and serotonin, with additional direct and downstream indirect effects on dopamine [12, 91], the mechanism of action responsible for its clinical efficacy is thought to be the result of its properties as a selective norepinephrine reuptake inhibitor. Phase III clinical trials investigating viloxazine ER, the ER formulation of viloxazine, have recently been completed, and demonstrate efficacy in reducing ADHD symptomatology in children and adolescents [36–39]. These studies demonstrate an acceptable incidence of adverse events, including cardiac-related adverse events, and pooled discontinuation rates because of TEAEs of 4.0% in viloxazine ER-treated groups and 1.2% among placebo groups [36–39, 68]. Given its mechanism of action and excellent safety and efficacy profile, viloxazine may be a useful alternative to stimulant or other nonstimulant therapy for the treatment of ADHD.

Acknowledgements Editorial assistance (proofreading, formatting, and medical writing support) was provided by IMPRINT Science (New York, NY, USA), and funded by Supernus Pharmaceuticals, Inc. We thank Rick Nullmeier for the research support, and Alisa Kosheleff for her help with the writing and editing of the article.

Declarations

Funding This review was funded by Supernus Pharmaceuticals, Inc. The open access fee was provided by Supernus Pharmaceuticals, Inc.

Conflict of interest Azmi F. Nasser, Stefan Schwabe, Chuning Yu, Jennie Garcia-Olivares, and Welton O’Neal are employees of Supernus Pharmaceuticals, Inc. At the time of this work, Shawn A. Candler was an employee of Supernus Pharmaceuticals, Inc. Robert L. Findling receives or has received research support, acted as a consultant and/or has received honoraria from Acadia, Adamas, Aevi, Afecta, Akili, Alkermes, Allergan, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Arbor, Axsome, Daiichi-Sankyo, Emelix, Gedeon Richter, Genentech, Idorsia, Intra-Cellular Therapies, Kempharm, Luminopia, Lundbeck, MedAvante-ProPhase, Merck, MJH Life Sciences, National Institutes of Health, Neurim, Osaka, PaxMedica, PCORI, Pfizer, Physicians Postgraduate Press, Q

△ Adis
BioMed, Receptor Life Sciences, Roche, Sage, Signant Health, Supernus Pharmaceuticals, Syneos, Syneurex, Takeda, Teva, Tris, and Validus. In the past year, Jeffrey H. Newcorn is has been an advisor and/or consultant for Adlon Therapeutics, Arbor, Corium, Eisai, Medice, Myriad Neuroscience, NLS, OnDosis, Rhodes, Shire/Takeda, and Supernus. He has received research support from the National Institute on Drug Abuse, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Otsuka, Shire, and Supernus. He also has received speaker fees from Shire/Takeda for disease-state presentations, and served as a consultant for the US National Football League.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Availability of Data and Material Not applicable.

Code Availability Not applicable.

Author contributions Conceptualization: RLF, JHN, SAC. Literature search: RLF, SAC, AFN, SS, CY, JGO, WON, JHN. Original draft preparation: RLF, SAC, AFN, SS, CY, JGO, WON, JHN. Reviewing and editing: RLF, JHN, SAC.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Mallion KB, Todd AH, Turner RW, Bainbridge JG, Greenwood DT, Madinaveitia J, et al. 2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride, a potential psychotropc agent. Nature. 1972;238:157–8.

2. Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13:401–21.

3. Renfordt E, Busch H, Fähndrich E, Müller-Oerlinghausen B. Studies on a novel antidepressant (viloxazin) by means of time-series analysis of TV data. Arzneimittelorschung. 1976;26(6):1114–6.

4. Marsh W. Viloxazine. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. Amsterdam: Elsevier Inc; 2007.

5. National Center for Biotechnology Information, PubChem database. Viloxazine, CID = 5666. https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine. Accessed 17 Jan 2019.

6. Mulrow CD. Treatment of depression: newer pharmacotherapies. Rockville: Agency for Health Care Policy and Research; 1999.

7. Kabeš J, Dostál T, Nahunek K, Svestka J, Molcan J, Caplová T, et al. Multicentre study with viloxazine (Vivalan®) in depressed patients. Int Pharmacopsychiatr. 1980;15:228–39.

8. US Food and Drug Administration. Orphan drug designations and approvals. Catatrol. https://www.accessdata.fda.gov/scripts/opedlisting/oped/detail/DetailIndex.cfm?cfgridkey=2384. Accessed 30 Apr 2020.

9. Williams D. Antidepressants. In: Lemke TL, Williams DA, Roche VF, Zito SW, editors. Foye’s principles of medicinal chemistry. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.

10. Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:122–5.

11. Blackburn TP, Foster GA, Greenwood DT, Howe R. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol. 1978;52:367–74.

12. Lippman W, Pugsley TA. Effects of viloxazine, an antidepressant, on biogenic amine uptake mechanisms and related activities. Can J Physiol Pharmacol. 1976;54:494–509.

13. Greenwood DT. Animal pharmacology of viloxazine (Vivalan). J Int Med Res. 1975;3:18–28.

14. Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxtryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978;17(6):421–3.

15. Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.

16. Jones RSG, Roberts MHT. Potentiation of responses to monoamines by antidepressants after destruction of monoamine afferents. Br J Pharmacol. 1979;69(3):501–10.

17. Jones RSG, Roberts MHT. Potentiation of monoamine responses of denervated cells by a noradrenergic uptake inhibitor (viloxazine). Br J Pharmacol. 1979;62(3):403P-404.

18. Cathala A, Devroye C, Drutel G, Revest JM, Artigas F, Spampinato U. Serotonin2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on serotonin neurons. Exp Neurol. 2019;311:57–66. https://doi.org/10.1016/j.expneur.2018.09.015.

19. Hall H, Sällemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol (Copenh). 1984;54(5):379–84.

20. Kalivas PW, Volkow N. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403–13.

21. Volkow N, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction. Arch Neurol. 2007;64(11):1575–9.

22. Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014;126(5):64–81. https://doi.org/10.3810/pgm.2014.09.2801.

23. Arnsten A. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry. 2006;67:7–12.

24. Arnsten AF. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I-S43. https://doi.org/10.1016/j.jpeds.2009.01.018.

25. Curatolo P, D’Agati E, Moavero R. The neurobiological basis of ADHD. Ital J Pediatr. 2010;36(1):79. https://doi.org/10.1186/1824-7288-36-79.

26. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry. 1991;25(2):277–83. https://doi.org/10.3109/00048679109077746.

27. Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct. 2008;4:12. https://doi.org/10.1186/1744-9081-4-12.
hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev. 2007;17(1):39–59. https://doi.org/10.1007/s11065-007-9019-9.

29. Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–70. https://doi.org/10.1016/j.neubiorev.2018.02.001.

30. Hutson PH, PenNick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropsychopharmacology. 2014;39:41–50. https://doi.org/10.1038/npp.2014.0214.

31. Hall H, Ogren SO. Effects of antidepressant drugs on histamine-H1 receptors in the brain. Life Sci. 1984;34(6):597–605.

32. Jones RSG. Long-term administration of atropine, imipramine, and viloxazine alters responsiveness of rat cortical neurones to acetylcholine. Can J Physiol Pharmacol. 1980;58(5):531–5.

33. Jones RSG, Roberts MHT. Modification of cortical neuron responses to acetylcholine by viloxazine. J Pharm Pharmacol. 1979;31:87–90.

34. Golds PR, Przyslo FR, Strange PG. The binding of some antidepresant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980;68:541–9.

35. Martinez C, Dominiak P, Kees F, Grobecker H. Inhibition of monoamine oxidase by viloxazine in rats. Drug Res. 1986;36(1):809–3.

36. Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al. A phase 3, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended release) in the treatment of ADHD in school-age children. Clin Ther. 2020;42(8):1452–66.

37. Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021. https://doi.org/10.1016/j.clinthera.2021.01.027.

38. Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021.

39. Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64.

40. Supernus Pharmaceuticals Inc. Supernus announces positive results from phase III study for SPN-812 in adults with ADHD. 2020. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-positive-results-phase-iii-study-spn812-0. Accessed 10 May 2021.

41. Bayliss PFC, Case DE. Blood level studies with viloxazine hydrochloride in man. Br J Clin Pharmacol. 1975;2:209–14.

42. Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, et al. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology. 1986;90:295–8.

43. Bayliss PFC, Dewsbury AR, Donald JF, Harcup JW, Mayer M, Million R, et al. A double-blind controlled trial of ‘Vivalan’ (viloxazine hydrochloride) and imipramine hydrochloride in the treatment of depression in general practice. J Int Med Res. 1974;2:260–4.

44. Case DE, Illston H, Reeves PR, Shuker B, Simons P. The disposition and metabolism of I.C.I. 838, a new psychotropic agent, in man. Br J Clin Pharmacol. 1974;5:121–8.

45. Bayliss PFC, Harcup JW, Mayer M, Million R, Murphy JE, Plant B, et al. An open study of two dose levels of ‘Vivalan’ (viloxazine hydrochloride ICI 58 834) in depression in general practice. J Int Med Res. 1974;2:253–9.

46. Ban TA, McEvoy JP, Wilson WH. Viloxazine: a review of the literature. Int Pharmacopsychiatr. 1980;15:118–23.

47. Bayliss PFC, Dewsbury AR, Donald JF, Harcup JW, Mayer M, Million R, et al. A double-blind controlled trial of ‘Vivalan’ (viloxazine hydrochloride) and imipramine hydrochloride in the treatment of depression in general practice. J Int Med Res. 1974;2:260-4.

48. Bayliss PFC, Harcup JW, Mayer M, Million R, Murphy JE, Plant B, et al. An open study of two dose levels of ‘Vivalan’ (viloxazine hydrochloride ICI 58 834) in depression in general practice. J Int Med Res. 1974;2:253–9.

49. Bayliss PFC, Harcup JW, Mayer M, Million R, Murphy JE, Plant B, et al. An open study of two dose levels of ‘Vivalan’ (viloxazine hydrochloride ICI 58 834) in depression in general practice. J Int Med Res. 1974;2:253–9.

50. Bouchard JM, Strub N, Nil R. Citalopram and viloxazine in the treatment of depression by means of slow drop infusion: a double-blind comparative trial. J Affect Disord. 1997;46:51–8.

51. Moizieszowicz J, Subirà S. Controlled trial of nomifensin (HOE 984) and viloxazine in the treatment of depression in the elderly. J Clin Pharmacol. 1977;17(1):81–3.

52. Brosnan RD, Bushy AM, Holland RP. Cases of overdosage with viloxazine hydrochloride (Vivalan). J Int Med Res. 1976;4:83–5.

53. Corona G, Frattini P, Cucchi M, Santagostino G, Schinelli S, Zerbi F, et al. Viloxazine in depressed women: clinical response and cardiovascular effects. Int J Clin Pharmacol Ther Toxicol. 1987;25(6):322–7.

54. Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, et al. Evaluation of the effect of SPN-812 (viloxazine extended release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):e1-6.

55. Bayliss PFC, Duncan SM. The clinical pharmacology of viloxazine hydrochloride: a new anti-depressant of novel chemical structure. Br J Clin Pharmacol. 1974;1:431–7.

56. Turner P, Bayliss PFC, Ghose K. Clinical pharmacology of viloxazine (Vivalan). J Int Med Res. 1975;3:41–7.

57. Meldrum B, Anlezark G, Adam H, Greenwood D. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology. 1982;76(3):212–7.

58. Edwards JG, Glen-Bott M. Does viloxazine have epileptogenic properties? J Neurol Neurosurg Psychiatry. 1984;47:960–4.

59. Pisani F, Fazio A, Oteri G, Pucca E, Russo M, Trio R, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49:1142–5.

60. Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:41–7.

61. Březinová V, Adam K, Chapman K, Oswald I, Thomson J. Viloxazine, sleep, and subjective feelings. Psychopharmacology. 1977;55:121–8.

62. Kirby M, Turner P. Some preliminary observations on ICI 58 834, a new psychotropic agent, in man. Br J Clin Pharmacol. 1973;1(2):169.

63. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999;46:1234–42.

64. Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52–68. https://doi.org/10.1016/j.neuint.2015.02.001.

65. Oades R. The role of the serotonin system in ADHD. Expert Rev Neurother. 2007;7:1357–74.

66. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209–25. https://doi.org/10.1177/1060028113510699.

67. Viggiano D, Ruocco LA, Arcieri S, Sadile AG. Involvement of norepinephrine in the control of activity and attentive processes in

Δ Adis
animal models of attention deficit hyperactivity disorder. Neural Plast. 2004;11(1–2):133-49.

68. Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, et al. A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–58.

69. Catala-Lopez F, Hutton B, Nunez-Beltran A, Page MJ, Ridao M, Macias Saint-Gerons D, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS ONE. 2017;12(7):e0180355. https://doi.org/10.1371/journal.pone.0180355.

70. Cortese S. Pharmacologic treatment of attention-deficit hyperactivity disorder. N Engl J Med. 2020;383(11):1050–6.

71. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652–8.

72. Wilens T. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65:38–45.

73. Soutullo C, DelBello MP, Ochsner JE, McElroy SL, Taylor SA, Strakowski SM, et al. Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord. 2002;70:323–7.

74. Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–13. https://doi.org/10.1542/peds.2010-1260.

75. Adler LA, Reingold LS, Morrill MS, Wilens TE. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409–15.

76. Mydayis (mixed salts of a single-entity amphetamine product) extended-release [package insert]. Lexington: Shire US, Inc.; 2019.

77. Adhansia XR (methylphenidate hydrochloride) extended-release [package insert]. Stamford: Purdue Pharma L.P.; 2019.

78. Treuer T, Gau SS, Mendez L, Montgomery W, Monk JA, Altin M, et al. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol. 2013;23(3):179–93. https://doi.org/10.1089/cap.2012.0093.